Lynn Kirkpatrick - May 25, 2022 Form 4 Insider Report for Ensysce Biosciences, Inc. (ENSC)

Role: Chief Executive Officer, Director
Signature: /s/ Lynn Kirkpatrick
Stock symbol: ENSC
Transactions as of: May 25, 2022
Transactions value $: $48,299
Form type: 4
Date filed: 5/27/2022, 02:05 PM
Previous filing: Feb 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENSC	Common Stock	Purchase	$34.1K	+70K	+24.57%	$0.49	355K	May 25, 2022	Direct
transaction	ENSC	Common Stock	Purchase	$14.2K	+27K	+7.61%	$0.53	382K	May 26, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENSC	Stock Option	Award		+200K	+8.63%		2.52M	Feb 17, 2022	Common Stock	200K	$1.40	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.

Content

On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.